Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart.
OBJECTIVE
The effects of tamsulosin treatment on changes in frequency-volume chart (FVC) data, especially nighttime urine production, over time were assessed, and the mechanisms underlying the improvement of nocturia in benign prostatic hyperplasia (BPH) patients with nocturnal polyuria (NP) are discussed.


METHODS
A total of 104 patients with lower urinary tract symptoms secondary to BPH were enrolled. After enrollment in the study, the patients were treated with tamsulosin (0.2 mg) once daily. Visits were scheduled every 4 weeks until week 12 (month 3) after study entry, and then every 12 weeks subsequently. All patients completed the International Prostate Symptom Score (IPSS), quality of life (QOL) index, and 3-day FVC, and underwent uroflowmetry at enrollment and on each visit.


RESULTS
Eighty-two patients (mean age: 70.9 ± 7.1 years) were analyzed for 24 months after treatment. Patients were divided into two groups, NP and nonNP, based on FVC outcome. The IPSS, QOL index, and maximum flow rate improved during the 24-month period after treatment in both groups. Mean daytime urine volume significantly increased in the NP group, but no changes were detected in the nonNP group. Mean nighttime urine frequency significantly decreased in the NP group over a 24-month period, and was associated with a significant decrease in nighttime urine volume that was not found in the nonNP group. Maximum voided volume increased most months after treatment in both groups.


CONCLUSIONS
The present long-term prospective study using FVC demonstrated that tamsulosin reduced nighttime urine production in BPH patients with NP.
Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. ykojima@med.nagoya-cu.ac.jp
Yoshiyuki
Y
Kojima
Shoichi
S
Sasaki
Makoto
M
Imura
Yasue
Y
Kubota
Yutaro
Y
Hayashi
Kenjiro
K
Kohri
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000368:Aged; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D053158:Nocturia / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D011141:Polyuria / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D015995:Prevalence; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications*; D011788:Quality of Life; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D014556:Urine / Q000502:physiology; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology
D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin